These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Bone marrow-derived EP3-expressing stromal cells enhance tumor-associated angiogenesis and tumor growth. Ogawa Y; Suzuki T; Oikawa A; Hosono K; Kubo H; Amano H; Ito Y; Kitasato H; Hayashi I; Kato T; Sugimoto Y; Narumiya S; Watanabe M; Majima M Biochem Biophys Res Commun; 2009 May; 382(4):720-5. PubMed ID: 19318087 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms. Huh JI; Calvo A; Stafford J; Cheung M; Kumar R; Philp D; Kleinman HK; Green JE Oncogene; 2005 Jan; 24(5):790-800. PubMed ID: 15592523 [TBL] [Abstract][Full Text] [Related]
12. Sex-steroid regulation of vascular endothelial growth factor in breast cancer. Hyder SM Endocr Relat Cancer; 2006 Sep; 13(3):667-87. PubMed ID: 16954424 [TBL] [Abstract][Full Text] [Related]
13. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease. Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844 [TBL] [Abstract][Full Text] [Related]
14. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones. Guo Y; Wang S; Hoot DR; Clinton SK J Nutr Biochem; 2007 Jun; 18(6):408-17. PubMed ID: 17142033 [TBL] [Abstract][Full Text] [Related]
15. Different cascades in the signaling pathway of two vascular endothelial growth factor (VEGF) receptors for the VEGF-mediated murine hepatocellular carcinoma development. Yoshiji H; Noguchi R; Kuriyama S; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Uemura M; Fukui H Oncol Rep; 2005 May; 13(5):853-7. PubMed ID: 15809749 [TBL] [Abstract][Full Text] [Related]
16. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor. Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116 [TBL] [Abstract][Full Text] [Related]
17. The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer. Bran B; Bran G; Hörmann K; Riedel F Int J Oncol; 2009 Jan; 34(1):255-61. PubMed ID: 19082496 [TBL] [Abstract][Full Text] [Related]
18. Constitutive and inducible expression and regulation of vascular endothelial growth factor. Xie K; Wei D; Shi Q; Huang S Cytokine Growth Factor Rev; 2004 Oct; 15(5):297-324. PubMed ID: 15450248 [TBL] [Abstract][Full Text] [Related]
19. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies. Pradeep CR; Sunila ES; Kuttan G Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy. Wood JM Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]